125 related articles for article (PubMed ID: 12853891)
1. Effect of combination of TS-1 and low-dose cisplatin on sarcoma-180 mouse sarcoma.
Suzuki Y; Ishibiki Y; Kawai K; Sasaki M; Matsuda M; Watanabe T; Shirasaka T; Kamano T
Anticancer Drugs; 2003 Jul; 14(6):475-9. PubMed ID: 12853891
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the anti-tumor activity of S-1 by low-dose cisplatin in mice bearing the sarcoma-180 model.
Yurimoto S; Miyakawa A; Okuzawa A; Sakamoto S; Sakamoto K; Hosoda S; Kamano T
Anticancer Drugs; 2005 Nov; 16(10):1109-14. PubMed ID: 16222153
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Shirasaka T; Shimamato Y; Ohshimo H; Yamaguchi M; Kato T; Yonekura K; Fukushima M
Anticancer Drugs; 1996 Jul; 7(5):548-57. PubMed ID: 8862723
[TBL] [Abstract][Full Text] [Related]
4. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Shirasaka T; Shimamoto Y; Kato T; Fukushima M
Gan To Kagaku Ryoho; 1998 Feb; 25(3):371-84. PubMed ID: 9492831
[TBL] [Abstract][Full Text] [Related]
5. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Yoshisue K; Hironaga K; Yamaguchi S; Yamamoto A; Nagayama S; Kawaguchi Y
Cancer Chemother Pharmacol; 2000; 46(1):51-6. PubMed ID: 10912578
[TBL] [Abstract][Full Text] [Related]
6. Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
Yamada Y; Hamaguchi T; Goto M; Muro K; Matsumura Y; Shimada Y; Shirao K; Nagayama S
Br J Cancer; 2003 Sep; 89(5):816-20. PubMed ID: 12942110
[TBL] [Abstract][Full Text] [Related]
7. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Nakaya T; Yonezawa H; Oyama K; Takahashi M; Saito K; Takechi T; Fukushima M; Shirasaka T
Eur J Cancer; 2003 Nov; 39(16):2387-94. PubMed ID: 14556932
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats.
Takechi T; Nakano K; Uchida J; Mita A; Toko K; Takeda S; Unemi N; Shirasaka T
Cancer Chemother Pharmacol; 1997; 39(3):205-11. PubMed ID: 8996521
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor activity and function of S-1, a new oral tegafur-based formulation].
Fukushima M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968
[TBL] [Abstract][Full Text] [Related]
11. [Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Shirasaka T; Yamamitsu S; Tsuji A; Terashima M; Hirata K
Gan To Kagaku Ryoho; 2000 Jun; 27(6):832-45. PubMed ID: 10897209
[TBL] [Abstract][Full Text] [Related]
12. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil.
Fukushima M; Shimamoto Y; Kato T; Uchida J; Yonekura R; Ohshimo H; Shirasaka T
Anticancer Drugs; 1998 Oct; 9(9):817-23. PubMed ID: 9840729
[TBL] [Abstract][Full Text] [Related]
13. [Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
Shirasaka T; Aiba K; Araki H; Suzuki M; Terashima M; Mikami Y
Gan To Kagaku Ryoho; 1999 Mar; 26(4):456-66. PubMed ID: 10097742
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
15. [A 13-week oral repeated dose toxicity study of a new antineoplastic agent S-1 in rats].
Hayashi T; Hasegawa H; Tanaka G; Ohmae S
J Toxicol Sci; 1996 Nov; 21 Suppl 3():505-26. PubMed ID: 9021659
[TBL] [Abstract][Full Text] [Related]
16. Alternate-day oral therapy with TS-1 for advanced gastric cancer.
Arai W; Hosoya Y; Hyodo M; Yokoyama T; Hirashima Y; Yasuda Y; Nagai H; Shirasaka T
Int J Clin Oncol; 2004 Jun; 9(3):143-8. PubMed ID: 15221596
[TBL] [Abstract][Full Text] [Related]
17. The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Peters GJ; Noordhuis P; Van Groeningen CJ; Giaccone G; Holwerda U; Voorn D; Schrijvers A; Schornagel JH; Beijnen JH; Fumoleau P; Schellens JH
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4072-6. PubMed ID: 15217941
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of a novel oral formation of 5-fluorouracil in combination with low-dose cisplatin as preoperative chemotherapy of oral squamous cell carcinoma.
Nakazawa M; Ohnishi T; Ohmae M; Chisoku H; Yui S; Iwai S; Sumi T; Fukuda Y; Kishino M; Yura Y
Int J Clin Pharmacol Res; 2005; 25(3):115-22. PubMed ID: 16366419
[TBL] [Abstract][Full Text] [Related]
19. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
20. [Oral single-dose toxicity study of a new antineoplastic agent S-1, and its components, CDHP, and Oxo].
Hayashi T; Tanaka G; Irimura K; Hirota T; Ohmae S
J Toxicol Sci; 1996 Nov; 21 Suppl 3():495-504. PubMed ID: 9021658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
